What is your approach to adjuvant therapy for an R0, ALK+ resected lung adenocarcinoma with N2 disease?

This is a timely question for me as well as the community. For me as I have just had my first patient presenting with ALK-positive 3A cancer PREOPERATIVELY. For the community as there was a recent presentation at ESMO of the ALINA trial. In the ALINA trial, patients with ALK-positive NSCLC were randomized to adjuvant alectinib vs chemotherapy following surgery (using the now "standard" cohort of patients with greater than 4 cm node negative tumors, or N1 and N2 positive tumors). 257 patients were randomized to alectinib for two years, or platinum based chemotherapy for four cycles. There was a substantial improvement in disease free survival for stage 2-3A patients as well as the overall population with a hazard ratio (HR) of 0.24 for the s...